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Natural killer (NK) cells are the primary effector cells of the innate immune system and 
have well-established roles in tumor rejection and resistance to viruses, bacteria and certain 
parasites. There is a need for more specific immune modulators of NK cell activity that lack 
the wide-ranging side effects of NK cell-stimulatory interleukins. The polycationic antibiotic 
polymyxin B (PMB) has been shown to have a unique ability to enhance activities of some 
immune cells, independent of its antibiotic properties. Here we report that both PMB and its 
analog polymyxin E (PME) markedly enhanced the activity of NK cells enriched from the 
murine spleen. Maximal activation of NK cell activity was obtained after 24 h of incubation 
with PMB at a dose of 300 μg/ml. PMB nonapeptide, one of the two PMB domains, and PME 
methanesulfonate, the negatively charged derivative of PME, had little effect on NK cell 
activity. PMB induced interferon (IFN)-γ and tumor necrosis factor-α production in NK cells. 
Proliferation of NK cells in vitro was significantly stimulated by being incubated with PMB. 
Administration of PMB to mice for 7 consecutive days stimulated splenic NK cell acitivity 
and increased NK cell populations in the spleen. These results suggest that the polycationc 
antibiotics PMB and PME may up-regulate innate and adaptive immune responses by 
induction of NK cell activity and IFN-γ production.  
 
 











Natural killer (NK) cells are the primary effector cells of the innate immune system and 
have well-established roles in tumor rejection in a variety of spontaneous and induced cancer 
models and resistance to viruses, bacteria and certain parasites [1-5]. The functions of NK 
cells are regulated by a complex balance of inhibitory and activating signals that allow them 
to selectively target and kill cells that display an abnormal pattern of cell surface molecules 
while leaving normal healthy cells unharmed. These signals are transmitted by inhibitory 
receptors that bind class I major histocompatibility complex (MHC) molecules and by 
activating receptors that bind ligands on tumors and pathogen-infected cells. Other than 
surface receptors, cytokines, such as interleukin (IL)-2, IL-12, IL-15, IL-18 and interferon 
(IFN)-α/β, have been shown to promote NK cell priming [6,7]. Clinical trials to enhance the 
anti-tumor potential of NK cells and the innate immune system have been performed over the 
last decade [8]. However, systemic administration of cytokines that regulate NK cell 
proliferation and/or activation perturb complex regulatory pathways, and serious side effects, 
including hypertension, cachexia, fever, chills, vomiting and diarrhea, have been observed 
[9-11]. There is an obvious need for more specific immune modulators that lack the 
wide-ranging side effects of the cytokines currently found in the clinical trials. 
Polymyxins B and E, which consist of a polycationic decapeptide and a fatty acid residue 
linked by an amide bond, show antibiotic activity against a diverse array of organisms, 
including bacteria, yeasts, and protozoa [12,13]. Polymyxin B (PMB) is especially active in 
causing permeabilization and killing of Gram-negative bacteria and has therefore been used 
for treating certain bacterial infections. Membrane disruption of the bacteria appears to be 
induced by interaction between PMB and bacterial phospholipids and lipopolysaccharide 
(LPS) in the outer membrane [12]. The high affinity of PMB for LPS is currently exploited to 
remove contaminating LPS from solutions and reagents, thus avoiding endotoxin shock or 
excluding the presence of potential LPS contaminations in experimental systems [14]. In 
addition to its abilities to neutralize LPS and kill microbes, PMB has been shown to enhance 
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activities of some immune cells: it activated B cells [15], induced maturation of 
monocyte-derived dendritic cells [16], and enhanced immunostimulatory sequence-induced 
IFN-α production in plasmacytoid dendritic cells [17]. Prompted by these reports indicating 
direct activity of PMB on innate immune cells, we examined the effect of PMB on activity of 
NK cells, the primary effector cells of the innate immune system. We found in this study that 
PMB remarkably enhanced murine NK cell cytolytic activity both in vitro and in vivo.  
 
2. Materials and methods 
 
   PMB sulfate salt, polymyxin E (PME, also known as colistin) sulfate salt, PME sodium 
methanesulfonate, and PMB nonapeptide hydrochloride were obtained from Sigma Chemical 
Co. (St. Louis, MO). Recombinant mouse IL-2 was purchased from Hoffmann-La Roche 
(Nutley, NJ). FITC-conjugated anti-mouse CD11c monoclonal antibody (mAb) was obtained 
from BD Biosciences Pharmingen (San Jose, CA). Anti-mouse IFN-γ mAb, biotinylated 
anti-mouse IFN-γ mAb, IFN-γ, TNF-α, and IL-12 were purchased from Endogen (Woburn, 
MA). Anti-mouse TNF-α antibody, biotinylated anti-mouse TNF-α antibody, anti-mouse 
IL-12 mAb, biotinylated anti-mouse IL-12 antibody, and a mouse IFN-α ELISA kit were 
obtained from R&D Systems (Minneapolis, MN). 
Female C57BL/6 mice were purchased from Charles River Japan, Inc. (Yokohama, Japan) 
and maintained under specific pathogen-free conditions in the animal facility of Okayama 
University. All experiments were performed according to the guidelines for animal 
experiments of Okayama University. Murine spleen cells from 8- to 12-week-old mice 
depleted of erythrocytes were prepared by lysis of erythrocytes with ammonium chloride. The 
spleen NK cells were enriched from erythrocyte-depleted spleen cells by negative selection 
using a mouse NK cell enrichment set (BD Biosciences Pharmingen) according to the 
manufacturer’s instructions, except that adherent cells were removed by incubating the cells 
on plastic dishes for 90 min at 37 °C before the procedure for negative selection. The purity of 
recovered viable NK cells ranged between 75 and 80% when the cells were stained with 
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PE-conjugated anti-mouse NK1.1 mAb (BD Biosciences Pharmingen), FITC-conjugated 
anti-mouse CD3 ε chain mAb (BD Biosciences Pharmingen) and propidium iodide after 
preincubation of the cells with anti-mouse CD16/CD32 mAb (BD Biosciences Pharmingen) 
and then analyzed by a flow cytometer (Epics XL, Beckman Coulter, Miami, FL). In some 
experiments, enriched NK cells were further purified by positive selection using a mouse NK 
cell separation set (BD Biosciences Pharmingen) according to the manufacturer’s instructions. 
The purification step resulted in 96-97% NK1.1+CD3- NK cells. 
For in vitro NK activity and cytokine production assays, NK cells (5 × 104 cells/200 
µl/well) were incubated for 24 h, unless otherwise specified, with or without PMB and other 
agents in RPMI 1640 medium, supplemented with 10% heat-inactivated fetal calf serum, 2 
mM L-glutamine, 50 µM 2-mercaptoethanol, 100 U/ml of penicillin G and 100 µg/ml 
streptomycin (complete medium), at 37℃ in an atmosphere containing 5% CO2 in 96-well 
round-bottom plates (Nunc, Roskilde, Denmark). NK cell activity was then determined by 
target cell retention of the fluorescent dye Calcein acetoxymethyl ester (Calcein-AM; 
Molecular Probes, Eugene, OR) [18-20]. Briefly, YAC-1 cells (106/ml of complete medium), 
obtained from Riken BRC Cell Bank (Tsukuba, Japan), were pre-incubated with 15 μM 
Calcein-AM for 30 min at 37℃ with occasional shaking and washed twice with the complete 
medium. The pre-cultured NK cells (effector cells) in the plate were washed once with the 
complete medium and incubated for 4 h with the YAC-1 cells (target cells, 104) at an E:T ratio 
of 5:1 in 200 μl/well of complete medium. Following the incubation, the plate containing cells 
was centrifuged at 420 × g for 10 min, and the resulting supernatant was removed from the 
cellular fraction by rapidly inverting the plate and flicking the supernatant out. The plate was 
blotted dry, and 200 µl of 2% Triton X-100 in 0.05 M borate buffer (pH 9.0) was added to 
each well. After incubation for 10 min at room temperature to solubilize remaining cells, 
individual wells were assayed for fluorescence with a microplate fluorometer (Fluoroskan). 
The wavelengths of the filters used were excitation at 485 nm and emission at 527 nm. The 
percentage of cytotoxic activity was calculated as: Cytotoxic activity (%) = (average 
fluorescence in wells incubated with target cells alone − fluorescence in the well of the 
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experimental group)/(average fluorescence in wells incubated with target cells 
alone − average fluorescence in wells incubated with effector cells alone) × 100. The IFN-γ 
level in each cultured supernatant was measured by an ELISA as described previously [20]. 
Levels of TNF-α, IL-12, and IFN-α in each cultured supernatant were measured by an ELISA 
according to the manufacturer’s instructions. 
For determination of DNA synthesis, NK cells (5 × 104 cells/200 µl/well) were incubated 
for 24 h with or without PMB. The cells were then pulse-labeled with [3H]thymidine (0.5 
μCi/well, 2.5 Ci/mmol) for 18 h and harvested on glass fiber filters using a cell harvester. The 
amount of [3H]thymidine incorporated was measured in a liquid scintillation counter. 
For determination of the in vivo effect of PMB on NK activity, erythrocyte-depleted 
spleen cells (1 × 106 cells/200 µl/well) from mice administered PMB instead of enriched NK 
cells were incubated with the target cells at E:T ratios of 25:1, 50:1 and 100:1 for the NK 
cytotoxicity assay described above.  
 
3. Results and discussion 
 
NK cells enriched by negative selection were incubated with PMB for 24 h, and their 
cytotoxic acitivity against YAC-1 target cells was assayed. NK cell activity was enhanced in a 
dose-dependent manner by 30−300 μg/ml of PMB (Fig. 1A). The effective concentrations are 
comparable to those previously reported for B cells and dendritic cells [15-17]. Maximal 
effect of PMB was observed at the concentration of 300 μg/ml, inducing a 7-fold increase in 
NK cell activity (Fig. 1A) and as marked as the effect of 5 U/ml of IL-2 (Fig. 1C). The 
activity of NK cells purified by negative plus positive selection was similarly enhanced by 
PMB (Fig. 1A). Incubation for 24 h or more was necessary for the full enhancing effect (Fig. 
1B). PME, in which D-phenylalanine of PMB cyclic peptide is replaced by D-leucine, was 
also effective (Fig. 1C). Both PMB and PME have two major domains: a polycationic 
decapeptide domain containing a heptapeptide ring and a fatty acid residue linked by an 
amide bond. In order to determine whether one or both domains are required to stimulate NK 
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cell activity, PMB nonapeptide and PME methanesulfonate were employed. PMB 
nonapeptide lacks the hydrophobic tail but retains the positively charged cyclic peptide 
domain. PME methanesulfonate is negatively charged instead of being positively charged, but 
the hydrophobic tail is intact. Neither PMB nonapeptide nor PME methanesulfonate had a 
notable effect on NK activity (Fig. 1C).      
It is known that IFN-γ is a key cytokine during innate and adaptive immune responses, 
and activated NK cells and T cells, which are the major types of innate and adaptive immune 
cells, respectively, produce IFN-γ [21,22]. We examined whether IFN-γ production is 
up-regulated in NK cells cultured with PMB and PME. As shown in Fig. 2A, both PMB and 
PME enhanced IFN-γ production as markedly as did 5 U/ml of IL-2. NK cells can produce 
TNF-α, and production of this cytokine is increased by activation with IL-2 [23,24]. PMB 
also enhanced TNF-α production as potently as did 5 U/ml of IL-2 in NK cells enriched by 
negative selection (Fig. 2B) and in NK cells purified by negative plus positive selection (data 
not shown). There were a very few dendritic cells in the both NK cell preparations purified by 
negative selection only and negative plus positive selection (less than 0.5% and 0.1%, 
respectively). Neither IFN-α nor IL-12 was detected in the culture supernatants of NK cells 
incubated with or without PMB (data not shown).      
In order to examine the in vivo effect of PMB on NK activity, mice were intraperitoneally 
administered PMB for 7 consecutive days, and NK activities of their splenocytes were 
determined. The splenic NK activity in mice treated with PMB significantly increased at all of 
the three different effector:target ratios (Fig. 3). PMB had no significant effect on body weight 
gain of mice during the experimental periods (data not shown). NK cell populations also 
significantly increased in the mice treated with PMB, as determined by flow cytometry (Fig. 
4A and 4B). Proliferation of NK cells in vitro was measured by being labeled with 
[3H]thymidine for the last 18 h during 42-h incubation with or without PMB. The antibiotic 
caused a significant increase in [3H]thymidine uptake by NK cells (Fig. 4C). 
PMB has been used due to its high affinity for LPS and being devoid of pleiotropic effects 
to exclude the presence of potential contaminations of LPS, a potent activator of innate 
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immune cells, in experimental systems. However, recent studies have shown that PMB is 
capable of directly activating some functions of dendritic cells [16,17]. We demonstrated in 
this study that PMB activated murine NK cells, the primary effector cells of the innate 
immune system, to kill tumor cells and produce IFN-γ and TNF-α at doses comparable to 
those effective on dendritic cells. To the best of our knowledge, this is the first report on the 
regulation of NK cell function by PMB. We also demonstrated stimulation of NK cell activity 
and proliferation by PMB administration in vivo.      
The mechanism responsible for PMB-induced NK cell activation has not been elucidated, 
but our studies using derivatives of PMB and PME suggested that both polycationic peptide 
and hydrophobic tail domains of the polymyxins are required for promoting cytolytic activity 
of NK cells. The two domains of PMB confer on the antibiotic the amphipathic property of 
solubilizing in water or lipid membranes, which is necessary for optimal membrane disruption 
of Gram-negative bacteria induced by the antibiotic. In contrast, it has been reported that 
polyanions such as heparin and dextran sulfate inhibit NK activity [25]. PMB is known as an 
inhibitor of protein kinase C (PKC) [26]. This activity of PMB, however, may not be involved 
in the activation of NK cells because PKC has been shown to play an important role in 
activating NK cell cytotoxicity and because the PKC inhibitor H-7 inhibited NK cell activity 
[27,28]. Valentinis et al. recently reported that PMB activates IκB-α/NF-κB and extracellular 
signal-regulated kinase (ERK)1/2 signal transduction pathways in human dendritic cells [16]. 
A recent study by Ortaldo et al. showed that both ERK and p38 mitogen-activated protein 
kinase (MAPK) pathways are required for the synergistic production of IFN-γ by 
cross-linking of activating Ly49D or NKG2D murine NK cell receptor combined with IL-12 
or IL-18 [29]. Thus, the ERK pathway is one of the candidates involved in PMB-induced 
activation of NK cells and IFN-γ production. In fact, we have obtained the results that the 
PMB-induced cytolytic activity of NK cells was inhibited by either the ERK kinase inhibitor 
PD98059 or the p38 MAPK inhibitor SB203580 (our unpublished data). Detailed biochemical 
and molecular analyses of PMB activity may provide new insights into the mechanism of NK 
cell activation. 
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Since NK cells are critical players during tumor growth control through a cytotoxic 
response and since IFN-γ plays a significant role in preventing development of primary and 
transplanted tumors [1,2,22], our experiments suggest that an anti-tumor effect of PMB 
should be investigated. Moreover, NK cells are capable of mediating antibody-dependent 
cellular cytotoxicity (ADCC) against an antibody-coated target via their expression of a 
low-affinity receptor for IgG (FcγRIII or CD16) [4]. Thus, our observations also suggest that 
PMB will become an effective adjuvant to administer in combination with anti-tumor 
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Legends for the Figures 
 
Fig. 1. Enhancement of murine NK cell cytotoxic activity in vitro by PMB. Murine NK cells 
enriched by negative selection were incubated for 24 h with the indicated doses of PMB (A), 
for the indicated periods with or without 300 μg/ml of PMB (B), and for 24 h with or without 
5 U/ml of IL-2 or 300 μg/ml of each of PME, PME methanesulfonate, PMB nonapeptide, and 
PMB (C). NK cells purified by negative plus positive selection were also incubated for 24 h 
with or without 300 μg/ml of PMB (A). The NK cell cytotoxic activity against YAC-1 tumor 
cells was then determined. The data are means ± S.D. of three independent experiments (A 
and C) or representative of two independent experiments with similar results (B). * p<0.05, 
** p<0.01, and *** p<0.001, as compared with the values of control cultures incubated in the 
medium alone (Dunnett’s t-test). 
 
Fig. 2. Induction of IFN-γ and TNF-α production in murine NK cells in vitro by PMB and 
PME. Murine NK cells enriched by negative selection were incubated for 24 h with or 
without 300 μg/ml of PMB, 300 μg/ml of PME or 5 U/ml of IL-2. The levels of IFN-γ (A) 
and TNF-α (B) in the culture supernatants were measured by an ELISA. The data are means ± 
S.D. of three independent experiments. ** p<0.01 and *** p<0.001, as compared with the 
values of control cultures incubated in the medium alone (Dunnett’s t-test). 
 
Fig. 3. Augmentation of splenic NK cell cytotoxic activity by intraperitoneal administration of 
PMB. Mice were intraperitoneally administered 5 mg/kg of PMB in 0.2 ml/head of saline or 
saline alone (control) for 7 consecutive days. NK cell cytotoxic activity of 
erythrocyte-depleted splenocytes against YAC-1 tumor cells was determined at the indicated 
E:T ratios. The data are means ± S.D. (n=4). * p<0.05 and ** p<0.01, as compared with the 
values of control mice (Student’s t-test). 
 
Fig. 4. Proliferation of splenic NK cells in vivo and in vitro induced by PMB. Mice were 
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intraperitoneally administered 5 mg/kg of PMB in 0.2 ml/head of saline or saline alone 
(control) for 7 consecutive days. Spleen cells were then stained with PE-conjugated NK1.1 
mAb and FITC-conjugated CD3 mAb and analyzed by a flow cytometer. Profiles (A) are 
representative of three mice in each group. A percentage of NK1.1+CD3- NK cell populations 
were shown in the profiles (A) and the graph (B). NK cells purified from spleen of untreated 
mice by negative plus positive selection were incubated with or without 300 μg/ml of PMB 
for 42 h, being pulse-labeled with [3H]thymidine for the last 18 h (C). The data are means ± 
S.D. (n=3). ** p<0.01, as compared with the values of control (Student’s t-test). 
